Últimas noticias sobre Dingdong (Cayman) (NYSE:DDL) Bolsa

Dingdong (Cayman)

Dingdong (Cayman) Ltd is the fastest growing on-demand e-commerce company in China. The company directly provides users and households with fresh produce, meat and seafood, and other daily necessities through a convenient shopping experience supported by an extensive self-operated frontline fulfillment grid. It recognizes revenues from product sales of fresh groceries and other daily necessities through Dingdong Fresh APP and mini-programs and membership services.

Dingdong (Cayman) Limited American Depositary Shares (each two representing three Ordinary Shares)

Dingdong (Cayman) Ltd

WisdomTree Dynamic Currency Hedged International SmallCap Equity Fund

Gorilla Technology Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) ("Gorilla" or the "Company") announced it has formally launched the initial phases of Thailand's largest-ever AI-driven energy transformation initiative with Thailand's Provincial Electricity Authority (the "Electricity Authority"). This significant moment took place in the presence of representatives of the Electricity Authority and representatives of the British Government, underscoring the global importance of this transformation.
This $1.8 billion initiative, spanning the next 15 years, is expected to digitally modernize Thailand's power infrastructure through AI, automation, and cybersecurity, ensuring greater efficiency, security, and sustainability. With this formal agreement, Gorilla and the Electricity Authority are now progressing into the structured definition phase, where the foundational scope, deployment strategies and operational frameworks will be developed.

News

GRRR

Gorilla Technology Says $1.8B Initiative, Spanning The Next 15-Years, Is Expected To Digitally Modernize Thailand's Power Infrastructure Through AI, Automation, And Cybersecurity, Ensuring Greater Efficiency, Security, And Sustainability

Gorilla Technology  Launches The Initial Phases Of Thailand's Largest-ever AI-driven Energy Transformation Initiative With Thailand's Provincial Electricity Authority

Board Reaffirms Recommendation that Shareholders Vote in Favor of Aptean Transaction
Logility Supply Chain Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGTY#NASDAQ">LGTY</a>) ("Logility" or the "Company"), a leader in AI-first supply chain management software, today announced that the unsolicited non-binding proposal to acquire all outstanding shares of Logility's common stock, previously announced on March 7, 2025 (the "Unsolicited Proposal"), has been withdrawn by the bidder. As a result, Logility has ceased discussions with the bidder regarding the Unsolicited Proposal.
Logility's definitive agreement to be acquired by Aptean, Inc. ("Aptean") for $14.30 per share in an all-cash transaction remains in full force and effect. The Logility Board of Directors reaffirms its existing recommendation that Logility's shareholders vote in favor of the transaction with Aptean.

Asset Sales

LGTY

Logility Maintains Recommendation For Shareholders To Support $14.30 Per Share Acquisition By Aptean After Unsolicited Non-Binding Proposal  Withdrawal

A-Mark Precious Metals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRK#NASDAQ">AMRK</a>) (A-Mark or the Company), a leading fully integrated precious metals platform, announced its continued expansion into the collectible coin market with the following acquisitions:
<ul>
<li>On February 28, 2025, A-Mark completed the previously reported acquisition of Spectrum Group International, Inc. (SGI), the parent of Stack's Bowers Galleries (SBG), one of the world's largest rare coin and currency auction houses and a leading wholesale and retail dealer specializing in numismatic and bullion products. SBG generated Total Revenue of $536.4 million and EBITDA of $10.9 million during the fiscal year ended June 30, 2024.</li>
<li>On March 9, 2025, A-Mark entered into a definitive agreement to acquire the 90% of AMS Holding, LLC (AMS) not owned by A-Mark. Founded in 1984, AMS operates the flagship brand GOVMINT where a team of over 150 dedicated sales representatives works with customers to assemble collections of vintage and modern coins.&nbsp;&nbsp; AMS generated Total Revenue of $203.8 million and Adjusted EBITDA of $9.3 million during the year ended December 31, 2024.</li>
<li>On February 28, 2025, A-Mark, closed the acquisition of the 51% of Pinehurst Coin Exchange, Inc. (Pinehurst) that it previously did not own. Founded in 2005, Pinehurst serves the wholesale and retail markets and is one of the nation's largest sellers of modern and numismatic coins on eBay. Pinehurst generated Total Revenue of $215.8 million and EBITDA of $7.7 million during the year ended December 31, 2024. &nbsp;</li>
</ul>

AMRK

A-Mark Expands Into The Collectible Coin Market With Acquisitions Of Stack's Bowers Galleries, AMS Holding, LLC, And Pinehurst Coin Exchange

A-Mark Precious Metals Acquires Stack's Bowers Galleries For $92M; Acquires AMS Holding For $50.0M; Acquires Pinehurst Coin Exchange For $6.5M

SenesTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>, ", SenesTech", or the ", Company", ))), a pioneer in fertility control solutions for managing rodent populations, announced today the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 374,718 shares of the Company's common stock originally issued by the Company on August 23, 2024, each having an original exercise price of $4.35 per share, at a reduced exercise price of $2.90 per share. In addition, the Company will issue new short-term warrants, as described below. The closing of the warrant exercise transaction is expected to occur on or about March 11, 2025, subject to Stockholder Approval (as defined herein) and satisfaction of customary closing conditions.
H.C. Wainwright is acting as the exclusive placement agent for the transaction.
The aggregate gross proceeds from the exercise of the existing warrants are expected to be approximately $1.1 million, before deducting placement agent fees and other offering expenses payable by the Company. The potential gross proceeds from the new short-term warrants, if fully exercised on a cash basis, will be approximately $4.3 million. No assurance can be given that any of the new short-term warrants will be exercised. The Company expects to use the net proceeds from the transaction for working capital and general corporate purposes.
The resale of the shares of common stock issuable upon the exercise of the existing warrants has been registered pursuant to an effective registration statement on Form S-3 (File No. 333-282286).

Offerings

SNES

SenesTech Announces Entry Into Definitive Agreements For The Immediate Exercise Of Certain Outstanding Warrants To Purchase An Aggregate Of 374,718 Shares Of Common Stock, Each Having An Original Exercise Price Of $4.35 Per Share, At A Reduced Exercise Price Of $2.90 Per Share For Gross Proceeds Of $1.1M

Management

Service Properties Trust Appoints Chris Bilotto As A Managing Trustee, President And Chief Executive Officer, Effective March 10, 2025

Strategy expects to make sales of perpetual strike preferred stock pursuant to the ATM Program in a disciplined manner over an extended period, taking into account the trading price and trading volumes of the perpetual strike preferred stock at the time of sale.
Strategy intends to use the net proceeds from the ATM Program for general corporate purposes, including the acquisition of bitcoin and for working capital.

MSTR

STRK

Strategy Announces $21B STRK At-The-Market Program

Biotech

General

HOTH

Hoth Therapeutics To Submit Expanded Access Application For HT-001

Stream Hatchet an influencer marketing company and live streaming analytics platform and wholly-owned subsidiary of GameSquare Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAME#NASDAQ">GAME</a>), ("GameSquare", or the "Company"), today announced a new contract with Capcom to support the launch of Monster Hunter Wilds. The contract is expected to contribute to GameSquare's revenue in 2025.
Under the terms of the contract, Stream Hatchet leveraged its best-in-class resources to help Capcom generate mass awareness for the release of the game, which has quickly become one of the most successful video game debuts of all time, breaking 1.3 million concurrent users on Steam, ranking 5th highest in Steam history and is Capcom's fastest selling game. Stream Hatchet's services include technology-enabled influencer discovery, talent sourcing, events production, and granular post-campaign performance analysis.
&nbsp;
"We are thrilled to be a part of one of the most successful video game launches of all time," stated Justin Kenna, GameSquare's CEO. "This contract with Capcom is a great example of the platform GameSquare and Stream Hatchet have created, highlighting our scale, technology, and best-in-class capabilities. Most importantly, it highlights Stream Hatchet's ability to leverage their leading technology and knowledge of gaming culture to produce successful outcomes for their customers."

Contracts

GAME

Stream Hatchet Enters Into A New Contract With Capcom To Support The Launch Of Monster Hunter Wilds

Preclinical Data Suggests Expanded Therapeutic Potential of the Hemopurifier&#xAE; Beyond Virology and Oncology
Results Support Further Evaluation of the Hemopurifier&#xAE;&nbsp;as Part of a Machine Perfusion Circuit to Further Assess its Impact on the Function of Retrieved Kidneys
SAN DIEGO, March 10, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4378620-1&amp;h=3653404512&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Faethlonmedical.com%2F___.YXAzOmFldGhsb246YTpvOmI3YWI2N2Q2OWRiZjI1MjAzMDg1MWYzYTRmNWQ4YjYxOjY6NjNiYTpmNzBkM2E2YjIwNTc2MDI1ZjRlZmJiMWVmMzQ5Mzg2MDJmMjk4M2EwZTcwOGM5NDUyOTJiNTY1NWFlNjFlYzhhOnA6VDpO&amp;a=Aethlon+Medical%2C+Inc.">Aethlon Medical, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases and for use in organ transplantation, today announced the publication of a pre-clinical study in&nbsp;the peer-reviewed journal Transplant Immunology (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4378620-1&amp;h=1949581366&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fdoi.org%2F10.1016%2Fj.trim.2025.102215___.YXAzOmFldGhsb246YTpvOjdmZGM3ZDI2M2E4NTU5MWQxY2Q4MmFkODkzNDUwYzZjOjY6NmNjYTo1OGI0ZWE0NTFhZDY1NGY0OGQ5ZWRjZGM5NmZlYWVkNjNhMzAzZmM5ZGQzZTZiZmNlMjIyYWM5NGI1NjdhODFkOnA6VDpO&amp;a=https%3A%2F%2Fdoi.org%2F10.1016%2Fj.trim.2025.102215">https://doi.org/10.1016/j.trim.2025.102215</a>) on February 28, 2025, entitled, " A lectin affinity plasmapheresis device removes extracellular vesicles and microRNAs from renal perfusates following controlled oxygenated rewarming of discarded donor kidneys."
Aethlon Medical's Hemopurifier&#xAE;&nbsp;is a therapeutic blood filtration system designed to bind and remove harmful extracellular vesicles and life-threatening viruses from blood and other biological fluids. Its capabilities have potential applications in oncology and infectious diseases, and organ transplantation.

AEMD

Aethlon Medical Publishes Preclinical Data On The Hemopurifier In Transplant Immunology Journal Entitled, " A Lectin Affinity Plasmapheresis Device Removes Extracellular Vesicles And MicroRNAs From Renal Perfusates Following Controlled Oxygenated Rewarming Of Discarded Donor Kidneys."

NET Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPWR#NYSE">NPWR</a>) reported quarterly losses of $(0.46) per share. This is a 235.29 percent decrease over earnings of $0.34 per share from the same period last year.

Earnings

NPWR

NET Power Q4 2024 GAAP EPS $(0.46) Down From $0.34 YoY

– Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair –
– Publication of the Budget Impact Model in peer-reviewed journal supports Symvess as a treatment that provides economic value to hospitals and payers –
DURHAM, N.C., March 10, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>), a biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the publication of the Budget Impact Model for Symvess in the Journal of Medical Economics. The publication, titled "Budget impact model of acellular tissue engineered vessel for the repair of extremity arterial trauma when autologous vein is not feasible," reported that Symvess was projected to be cost saving for both trauma centers and third-party payers, primarily due to reductions in the costs related to amputations and conduit infections.

HUMA

Humacyte Announces Symvess Cost-Saving Benefits In Journal Of Medical Economics; Supports Economic Value For Hospitals And Payers

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>Dividend Yield: 4.01%</li>
<li>Truist Securities analyst David Macdonald maintained a Buy rating and raised the price target from $60 to $76 on Feb. 13, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Leerink Partners analyst Michael Cherny upgraded the stock from Market Perform to Outperform and boosted the price target from $55 to $75 on Feb. 13, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On March 4, Wellvana and CVS Health disclosed that Wellvana has acquired the Medicare Shared Savings Program business of CVS Accountable Care&#x2122;, part of CVS Health, in an all-stock transaction.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1">CVS news</a>. </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/59c9cf91-f220-445e-9cc8-fb8e60e12227" alt="" style="width:620px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.06%</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $60 to $62 on Feb. 7, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and boosted the price target from $60 to $65 on Jan. 28, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On March 7, the European Commission (EC) approved Bristol Myers Squibb's Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC), a type of liver cancer.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1">BMY news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="910" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221826/image-43.png" alt="" class="wp-image-815700" style="width:563px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221826/image-43.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221826/image-43-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221826/image-43-768x701.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<h3 class="wp-block-heading">Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</h3>
<ul>
<li>Dividend Yield: 2.98%</li>
<li>Guggenheim analyst Vamil Divan maintained a Neutral rating and raised the price target from $162 to $166 on Feb. 3, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Barclays analyst Matt Miksic maintained an Equal-Weight rating and increased the price target from $159 to $166 on Jan. 28, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On March 7, Johnson &amp; Johnson decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor (KOR) antagonist, as an adjunctive treatment for major depressive disorder (aMDD).</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1">latest JNJ news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="905" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221911/image-44.png" alt="" class="wp-image-815702" style="width:570px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221911/image-44.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221911/image-44-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221911/image-44-768x702.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44187903/top-2-consumer-stocks-that-could-blast-off-this-quarter">Top 2 Consumer Stocks That Could Blast Off This Quarter</a></li>
</ul>

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

GDOT

Green Dot Announces Review of Strategic Alternatives; Co. Also Appoints William I Jacobs As Interim CEO

NV5 Global, Inc. (the "Company" or "NV5") (NASDAQ:<a href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>), a provider of technology, certification, and consulting solutions, announced today that it has been awarded $18 million in recent data center design and commissioning contracts throughout the U.S. and Asia, reinforcing its position as a leader in the rapidly expanding data center sector. These new agreements amplify NV5's role in developing and optimizing infrastructure to meet the growing demands for cloud computing and AI-driven operations.
NV5 will implement high-efficiency cooling and power distribution testing, inspection, certification and design solutions for both new and retrofitted facilities. With the growing strain on electrical infrastructure from AI workloads, NV5's proven expertise in sustainable design and operational resilience has become a valued resource for clients seeking innovative solutions to scale their data center capabilities.

NVEE

NV5 Global Has Been Awarded $18M In Recent Data Center Design And Commissioning Contracts Throughout The U.S. And Asia

New data showed that a single dose of a tumor-selective triple knockout ("3KO") RT virus with a specific immunotherapeutic payload (undisclosed) has dramatically altered the tumor microenvironment, characterized by marked increases in CD45+ leukocytes, CD3+ and CD8+ T cells. Specifically, the leukocyte infiltration reached 80% for 3KO RT and 92% for the 3KO RT with the payload, compared to 46% for the untreated arm. These new data confirm the production of immunomodulated payload specifically at the tumor sites. These significant shifts in immune composition, driven by 3KO RT with payload, ultimately led to complete eradication of certain tumors in the preclinical model.

CLDI

Calidi Biotherapeutics Highlights Delivery Of Transient Gene Therapy (Payload) To Tumors Using Systemic Platform

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.becn.com%2F&amp;esheet=54221248&amp;newsitemid=20250310934468&amp;lan=en-US&amp;anchor=Beacon&amp;index=1&amp;md5=5a8b2212562735e5fa58f90845210a9a">Beacon</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BECN#NASDAQ">BECN</a>), the leading publicly-traded specialty wholesale distributor of roofing, waterproofing and related exterior products, announced today a strategic investment and partnership with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.renovaterobotics.com%2F&amp;esheet=54221248&amp;newsitemid=20250310934468&amp;lan=en-US&amp;anchor=Renovate+Robotics&amp;index=2&amp;md5=73c6a2b93490e4dee8cf628482d88b4b">Renovate Robotics</a> - a pioneer in roofing automation.
Renovate Robotics, based in Brooklyn, New York, is the leading startup developing autonomous roofing robots with a focus on making roofing safer and more productive for contractors. Their first robot, Rufus, installs asphalt shingles on residential roofs and is expected to launch with contractors in New Jersey and Pennsylvania later this year.

BECN

Beacon Announced Strategic Investment In Renovate Robotics For Roofing Automation; Terms Not Disclosed

BYON

Beyond Board Appoints Executive Chairman Marcus Lemonis As Principal Executive Officer And Adrianne Lee As President & CEO

HC Wainwright &amp; Co. analyst Oren Livnat maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and raises the price target from $200 to $217.

JAZZ

HC Wainwright & Co. Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $217

Press Releases

Dingdong Files Its Annual Report on Form 20-F

Dingdong to Report First Quarter 2024 Financial Results on May 13, 2024

Dingdong (Cayman) Limited Announces First Quarter 2024 Financial Results

Dingdong to Report Second Quarter 2024 Financial Results on August 7, 2024

Dingdong (Cayman) Limited Announces Second Quarter 2024 Financial Results

Dingdong to Report Third Quarter 2024 Financial Results on November 6, 2024

Dingdong (Cayman) Limited Announces Third Quarter 2024 Financial Results

Dingdong to Report Fourth Quarter 2024 Financial Results on March 6, 2025

Dingdong Announces US$20.0 Million Share Repurchase Program

Dingdong (Cayman) Limited Announces Fourth Quarter 2024 Financial Results

Albertsons Companies, Inc. Class A Common Stock

Albertsons Companies

Maplebear

Caseys General Stores, Inc. - Common Stock

Casey's General Stores

Chanson International Holding - Class A Ordinary Shares

Chanson International

Grocery Outlet Holding Corp. - Common Stock

Grocery Outlet Holding

Ingles Markets, Incorporated - Class A Common Stock

Ingles Markets

Kroger

Maison Solutions Inc. - Class A Common Stock

Maison Solutions

Natural Grocers by Vitamin Cottage, Inc. Common Stock

Natural Grocers

Reborn Coffee

Sprouts Farmers Market, Inc. - Common Stock

Sprouts Farmers Market

BBB Foods

Village Super Market, Inc. - Class A Common Stock

Village Super Market

Weis Markets

Meiwu Technology Company Limited - Ordinary Shares

Comments

Dingdong (Cayman)

Noticias

Últimas noticias sobre Dingdong (Cayman) (NYSE:DDL) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL